epiglucan has been researched along with Pneumococcal-Infections* in 4 studies
1 review(s) available for epiglucan and Pneumococcal-Infections
Article | Year |
---|---|
Respiratory infections in HIV-infected adults: epidemiology, clinical features, diagnosis and treatment.
Using the evidence published over the last 2 years, this review discusses the epidemiology, diagnosis, treatment and prevention of HIV-related pulmonary infections other than mycobacterial disease.. Longstanding, vertically acquired and apparently stable HIV infection is associated with significant and symptomatic small airways disease in African adolescents. The use of population-based pneumococcal vaccination in children is changing the severity and serotypes associated with HIV-related pneumococcal disease. Data on the use of blood 1,3,β-D-glucan show it has promise as a rule-out test for Pneumocystis pneumonia (PCP).. With widespread antiretroviral medication usage, the pattern of HIV-associated pulmonary disease is changing. Whereas opportunistic infections such as PCP still occur in people not using antiretroviral therapy (ART), HIV-related infections are similar to those present in the general population. Chronic lung disease is more prevalent, leading to its own infectious complications. The use of specific immunizations against infections is important, though their precise benefit with concomitant widespread ART and population-based vaccination programmes in the non-HIV community is undetermined. Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; beta-Glucans; HIV Infections; Humans; Lung Diseases; Pneumococcal Infections; Respiratory Tract Infections | 2013 |
3 other study(ies) available for epiglucan and Pneumococcal-Infections
Article | Year |
---|---|
False-positive elevation of 1,3-beta-D-glucan caused by continuous administration of penicillin G.
The 1,3-beta-D-Glucan (BDG) assay is widely used for the diagnosis of fungal infections, especially in patients with hematologic malignancies. Some antimicrobials have been reported to cause false-positive results for BDG, but there has been no report on the effect of penicillin G (PCG) on BDG levels. We experienced a patient who developed false-positive BDG elevation during the administration of PCG for osteomyelitis due to Streptococcus pneumoniae infection. The serum BDG level increased up to 81.0 pg/ml during the continuous administration of PCG at 24 million units per day. However, chest and paranasal CT scan showed no evidence of fungal infection. The BDG level decreased to 38.0 pg/ml at 14 hours after the discontinuation of PCG. The amount of BDG in one vial of PCG inferred from these serum BDG levels is very similar to the actual BDG concentration in a vial of PCG. Therefore, during the administration of PCG, elevated BDG levels should be interpreted with caution, as they may be false-positive results. Topics: Anti-Bacterial Agents; beta-Glucans; False Positive Reactions; Humans; Male; Middle Aged; Osteomyelitis; Penicillin G; Pneumococcal Infections; Streptococcus pneumoniae | 2018 |
Protective effect of beta-glucan against systemic Streptococcus pneumoniae infection in mice.
The antimicrobial effect of soluble beta-1,3-D-glucan from Sclerotinia sclerotiorum (SSG) was examined in mice experimentally infected intraperitoneally (i.p.) with Streptococcus pneumoniae serotypes 4 and 6B. SSG was administered i.p. either 3 days before challenge or 3-48 h after challenge. The number of bacteria in blood samples and the mouse survival rates were recorded. Pre-challenge SSG administration protected dose-dependently against both S. pneumoniae type 4 and 6B infections. SSG injected 24 h post-challenge had a curative effect against type 6B but not type 4 pneumococcal infection. The data demonstrate that SSG administered systemically protects against pneumococcal infection in mice. Topics: Animals; Antibodies, Bacterial; Bacteremia; beta-Glucans; Colony Count, Microbial; Female; Glucans; Humans; Mice; Pneumococcal Infections; Streptococcus pneumoniae; Survival Rate | 2000 |
In vivo activation of mouse macrophages with beta-1,3-D-glucan-derivatized plastic beads.
Macrophages obtained from animals treated with beta-1,3-D-glucan-derivatized plastic beads were greatly stimulated, as judged by morphology, esterase release, and cytostatic effect on L-929 tumour cells in vitro. The pretreatment of mice with such beads conferred an apparent absolute local resistance to an otherwise lethal pneumococcal infection but had no effect on the growth of intraperitoneal AA ascites sarcoma. Moreover, peritoneal cells from animals pretreated with glucan beads did not protect the animals in a Winn assay. Topics: Animals; beta-Glucans; Cell Division; Cell Line; Esterases; Glucans; Leukemia; Macrophage Activation; Macrophages; Melanoma; Mice; Mice, Inbred C57BL; Microspheres; Pneumococcal Infections | 1985 |